The study is backed by Bayer (OTC:BAYRY) (ETR: BAYN) and the Ramsay Hospital Research Foundation and will be led by Professor Lisa Horvath from Chris O'Brien Lifehouse and the Australian and New ...

Bayer will provide a minimum of $300 million in R&D investments to the JV over the next five years, and will acquire a minority stake in CRISPR Therapeutics for $35 million in cash.

TEL-AVIV, Israel and RALEIGH, N.C. - RedHill Biopharma Ltd. (NASDAQ: NASDAQ:RDHL), a specialty biopharmaceutical company with a market capitalization of $7.53 million, today announced the initiation ...

DES MOINES, Iowa (AP) — A renewed and expanded effort from chemical giant Bayer to shield itself from lawsuits that claim its ...

Although Bayer’s top-selling drug Xarelto lost market exclusivity in most geographies in 2024, the company still predicts it will see strong growth from the pharma business unit beginning in 2027.

That marks a reversal of comments he made at the same meeting a year ago. Bayer now has built the drug pipeline it needs to grow in the next five to seven years, he said. “Acquisitions are ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

Bayer has advanced its small-molecule drug BAY 2927088 into phase 3 for non-small cell lung cancer (NSCLC) with HER2 activating mutations, one of the drugs central to the company’s plan to ...

Bayer's shares sink to 20-year low on 2025 earnings ... giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by Novo Nordisk's controlling shareholder ...

However, EPCT operations suffer from numerous inefficiencies, such as cumbersome start-up processes, which are particularly critical when drug safety and the recommended ... Amgen (Inst), Pierre Fabre ...